#MRSA Antibiotics market insights | Explore Tumblr Posts and Blogs

priyanshisingh · 4 months

Text

Nosocomial Infection Treatment Market Insights: Comprehensive Global Forecast (2023-2032)

The global demand for nosocomial infection treatment was valued at USD 30154.56 Million in 2023 and is expected to reach USD 35720.76 Million in 2032, growing at a CAGR of 1.90% between 2024 and 2032.

The nosocomial infection treatment market is experiencing significant growth driven by the increasing incidence of hospital-acquired infections (HAIs), advancements in diagnostic techniques, and the development of new and effective treatment options. Nosocomial infections, also known as healthcare-associated infections, are infections that patients acquire while receiving treatment for other conditions within a healthcare setting. Common HAIs include infections like methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), urinary tract infections, pneumonia, and surgical site infections. The rising prevalence of these infections is attributed to factors such as the growing number of surgical procedures, prolonged hospital stays, the increasing use of invasive devices like catheters and ventilators, and the spread of antibiotic-resistant bacteria.

Advancements in diagnostic technologies are playing a crucial role in the early detection and management of nosocomial infections. Rapid diagnostic tests and molecular diagnostic tools have significantly improved the ability to quickly identify pathogens, allowing for timely and targeted treatment. This is particularly important in controlling the spread of infections within healthcare facilities and improving patient outcomes. Additionally, the development of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies has enabled precise identification of microbial strains, aiding in the selection of appropriate antimicrobial therapies.

The treatment landscape for nosocomial infections is evolving with the introduction of new antibiotics, antifungals, and antiviral agents. The growing problem of antibiotic resistance has spurred research and development efforts to discover novel antimicrobial agents that are effective against resistant strains. Pharmaceutical companies are also exploring combination therapies that enhance the efficacy of existing antibiotics and reduce the risk of resistance development. Immunotherapy and bacteriophage therapy are emerging as promising alternatives, offering targeted approaches to infection treatment.

The key findings of the study on the nosocomial infection treatment market highlight the current state of the market, its driving factors, challenges, and future prospects. These findings provide valuable insights into the dynamics of the market and its growth trajectory. Here are the key findings:

1. Rising Incidence of Nosocomial Infections

The study reveals a significant increase in the prevalence of hospital-acquired infections (HAIs) globally. Factors contributing to this rise include the growing number of surgical procedures, increased use of invasive devices, longer hospital stays, and the spread of antibiotic-resistant bacteria. Common HAIs such as MRSA, C. difficile, urinary tract infections, pneumonia, and surgical site infections are major concerns for healthcare facilities.

2. Advancements in Diagnostic Technologies

Rapid advancements in diagnostic technologies are enhancing the early detection and precise identification of pathogens causing HAIs. The development and adoption of rapid diagnostic tests, molecular diagnostics, next-generation sequencing (NGS), and polymerase chain reaction (PCR) techniques are improving the speed and accuracy of diagnosis. This allows for timely and targeted treatment, ultimately improving patient outcomes and controlling the spread of infections.

3. Emergence of Novel Antimicrobial Agents

The growing problem of antibiotic resistance is driving research and development efforts to discover new antimicrobial agents. Pharmaceutical companies are focusing on the development of novel antibiotics, antifungals, and antiviral agents that are effective against resistant strains. Combination therapies, immunotherapy, and bacteriophage therapy are emerging as promising treatment approaches, offering targeted solutions to combat resistant infections.

4. Importance of Infection Control Measures

The study emphasizes the critical role of infection control measures in reducing the incidence of HAIs. Healthcare facilities are increasingly adopting stringent hygiene practices, antimicrobial stewardship programs, and advanced sterilization and disinfection technologies. The implementation of infection control guidelines and protocols by regulatory bodies such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) has further bolstered efforts to prevent HAIs.

5. Aging Population and Chronic Diseases

The growing aging population and the rise in chronic diseases such as diabetes and cancer contribute to the increased risk of HAIs. Older adults and individuals with chronic conditions often require frequent hospital visits and medical procedures, making them more susceptible to infections. This demographic trend underscores the need for effective nosocomial infection treatments and preventive measures.

6. Regional Variations

The study identifies regional variations in the nosocomial infection treatment market. North America and Europe dominate the market due to their advanced healthcare infrastructure, high healthcare expenditure, and strong regulatory frameworks. The Asia-Pacific region is expected to witness the fastest growth, driven by increasing healthcare investments, rising awareness about infection control, and the growing burden of HAIs in countries like China and India. Latin America and the Middle East and Africa are gradually improving their healthcare systems, focusing on enhancing infection control measures.

7. Competitive Landscape

The market is highly competitive, with major players focusing on strategic collaborations, mergers and acquisitions, and product innovations to strengthen their market positions. Leading companies such as Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, and GlaxoSmithKline plc are continuously investing in R&D to develop new antimicrobial agents and improve existing treatments. Emerging players are also contributing to market growth with innovative solutions and targeted therapies.

8. Future Prospects

The nosocomial infection treatment market is poised for robust growth, driven by the rising prevalence of HAIs, advancements in diagnostic and therapeutic technologies, and increased efforts towards infection prevention and control. The continuous evolution of treatment options, the implementation of stringent infection control measures, and the growing adoption of advanced technologies will be crucial in addressing the challenges posed by nosocomial infections and improving patient care outcomes in healthcare settings.

Key Players:

3M Company

Abbott Laboratories

Advanced Sterilization Products Services Inc. (ASP)

Becton, Dickinson and Company (BD)

Belimed AG

BioMérieux SA

Cantel Medical Corp.

Getinge Group

Johnson & Johnson

Merck & Co., Inc.

Pfizer Inc.

Roche Diagnostics Corporation

Stryker Corporation

Thermo Fisher Scientific Inc.

Steris Corporation

Zimmer Biomet Holdings, Inc.

Ansell Limited

Molnlycke Health Care AB

Cantel Medical Corp.

More About Report- https://www.credenceresearch.com/report/nosocomial-infection-treatment-market

The nosocomial infection treatment market exhibits distinct regional characteristics, driven by variations in healthcare infrastructure, regulatory frameworks, awareness levels, and prevalence of hospital-acquired infections (HAIs). Here's an overview of the regional insights:

North America

Key Characteristics:

Advanced Healthcare Infrastructure: North America, particularly the United States, boasts a highly advanced healthcare system with well-equipped hospitals and clinics. This supports the adoption of advanced diagnostic and treatment technologies for nosocomial infections.

High Healthcare Expenditure: The region's significant healthcare spending enables substantial investment in infection control measures, antimicrobial research, and the implementation of advanced treatment protocols.

Strong Regulatory Framework: Agencies like the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) enforce stringent guidelines and regulations for infection control and the approval of new treatments.

Research and Development Hub: North America is a major hub for pharmaceutical and biotechnology research, leading to the continuous development of novel antimicrobial agents and diagnostic tools.

Europe

Key Characteristics:

Robust Infection Control Policies: Europe has established comprehensive infection control policies and guidelines, supported by organizations such as the European Centre for Disease Prevention and Control (ECDC).

High Awareness and Education: There is a high level of awareness and education regarding HAIs among healthcare professionals and the general public, promoting adherence to hygiene and infection control practices.

Government Initiatives: European governments actively invest in healthcare infrastructure and infection control programs, facilitating better management and treatment of nosocomial infections.

Collaborative Research: Europe benefits from collaborative research initiatives and funding from the European Union, driving advancements in diagnostics and treatments for HAIs.

Asia-Pacific

Key Characteristics:

Rapidly Developing Healthcare Infrastructure: The Asia-Pacific region is experiencing rapid growth in healthcare infrastructure, particularly in countries like China, India, and Japan. This expansion supports the increased adoption of advanced medical technologies.

Rising Prevalence of HAIs: The growing burden of HAIs in densely populated countries necessitates effective infection control and treatment strategies.

Increasing Healthcare Investments: Governments in the region are investing heavily in healthcare improvements, including infection prevention and control measures.

Awareness and Education Campaigns: Efforts to raise awareness about the importance of infection control are gaining momentum, leading to better implementation of hygiene practices and protocols.

Latin America

Key Characteristics:

Developing Healthcare Systems: Latin American countries are working towards improving their healthcare systems, with a focus on enhancing infection control measures and access to advanced treatments.

High Burden of HAIs: The prevalence of HAIs is relatively high, driving the need for effective diagnostic and therapeutic solutions.

Government and NGO Initiatives: Both government bodies and non-governmental organizations (NGOs) are playing active roles in promoting infection control and funding healthcare improvements.

Middle East and Africa

Key Characteristics:

Emerging Healthcare Infrastructure: The region is witnessing gradual improvements in healthcare infrastructure, with a focus on modernizing hospitals and clinics.

High Infection Rates: The high incidence of HAIs, coupled with limited resources, presents significant challenges in infection control and treatment.

Government Efforts: Governments are increasingly prioritizing healthcare investments and infection control programs to address the rising burden of HAIs.

International Support: International organizations and partnerships are providing support for healthcare improvements and infection control initiatives.

Segmentation:

By Type of infection

Urinary Tract Infections (UTIs)

Surgical Site Infections (SSIs)

Pneumonia

Bloodstream Infections

Gastrointestinal Infections

Skin and Soft Tissue Infections

By Treatment Type

Antibiotics

Antifungal Agents

Antiviral Drugs

Surgical Interventions

Supportive Care

By End User

Hospitals

Long-Term Care Facilities

Ambulatory Surgical Centers

Clinics and Outpatient Settings

Home Healthcare

Browse the full report – https://www.credenceresearch.com/report/nosocomial-infection-treatment-market

Browse Our Blog: https://www.linkedin.com/pulse/nosocomial-infection-treatment-market-pmq0f

Phone: +91 6232 49 3207

Email: [email protected]

Website: https://www.credenceresearch.com

0 notes

delicatemagazinedreamer · 1 year

Text

Antimicrobial Therapeutics Market Is Estimated To Witness High Growth Owing To Increasing Resistance to Antibiotics

The global Antimicrobial Therapeutics Market is estimated to be valued at US$ 219.80 billion in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Antimicrobial Therapeutics market comprises various pharmaceutical products that are used to treat microbial infections. These therapeutics play a crucial role in managing and treating diseases caused by bacteria, viruses, fungi, and parasites. The major advantages of antimicrobial therapeutics include their ability to effectively target specific pathogens and their potential for minimal side effects. The need for these products arises from the increasing prevalence of antimicrobial resistance, which has become a global health concern. Antimicrobial therapeutics are essential for combating the growing resistance to antibiotics and ensuring effective treatment options. Market Key Trends: One key trend driving the growth of the Antimicrobial Therapeutics market is the increasing resistance to antibiotics. Over the years, microbes have developed resistance to commonly used antibiotics, rendering them ineffective in treating infections. This has led to the need for alternative antimicrobial therapeutics that can target drug-resistant pathogens. For example, the emergence of antibiotic-resistant strains of bacteria such as Methicillin-Resistant Staphylococcus Aureus (MRSA) has created a demand for novel therapeutics such as antimicrobial peptides, which have shown efficacy against resistant strains. This trend presents significant opportunities for market players to develop innovative therapeutics to address the challenge of antimicrobial resistance. PEST Analysis: Political: Governments worldwide have taken initiatives to combat antimicrobial resistance through policies and regulations. For instance, the World Health Organization developed a Global Action Plan on Antimicrobial Resistance to provide guidelines for countries to mitigate the risks associated with drug-resistant pathogens. Economic: The Antimicrobial Therapeutics market is driven by both the public and private sector investments. Governments and healthcare organizations are allocating funds to support research and development activities for developing new antimicrobial therapeutics. Moreover, the rising healthcare expenditure and the increasing demand for effective treatment options are expected to drive market growth. Key Takeaways: 1) Market size related content: The global Antimicrobial Therapeutics Market Share is expected to witness high growth, exhibiting a CAGR of 4.8% over the forecast period. This growth can be attributed to increasing resistance to antibiotics, which has created a demand for alternative therapeutics. For example, companies like Pfizer Inc., Johnson & Johnson, and GlaxoSmithKline plc are investing in research and development activities to develop novel antimicrobial products. 2) Regional analysis related content: North America is expected to dominate the Antimicrobial Therapeutics market due to the presence of major pharmaceutical companies and a well-established healthcare infrastructure. However, Asia Pacific is anticipated to be the fastest-growing region during the forecast period. This can be attributed to increasing awareness about antimicrobial resistance, rising healthcare expenditure, and growing investments in research and development activities. 3) Key players related content: Key players operating in the global Antimicrobial Therapeutics market include Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Roche Holding AG, AstraZeneca plc, Sanofi SA, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., AbbVie Inc., Allergan plc, and Mylan N.V. These companies are focusing on strategic partnerships, mergers and acquisitions, and investments in research and development to strengthen their market position and develop innovative antimicrobial therapeutics.

0 notes

abrreports-blog · 4 years

Text

MRSA Antibiotics Market Key Trends, Drivers, Growth Opportunities, and 2025 Industry Chain Structure Analysis

The research study MRSA Antibiotics market 2020 launched by ABRReports.com provides the detailed analysis of current market status, investment plans, production and consumption, price trends, leading key companies, growth drivers and future prospect. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025

Get the Sample Copy of MRSA Antibiotics market report at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-mrsa-antibiotics-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

The segmentation of MRSA Antibiotics study as mentioned below:

By Market Players:

Pfizer, Sanofi, Novartis

By Application

Adults, ChildrenVancomycin, Teicoplanin, Linezolid, Cubicin, Others

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-mrsa-antibiotics-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

The key objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Purchase the research study @ https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-mrsa-antibiotics-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

Key pointers of the Table of Contents:

Chapter 1 Industry Overview

Chapter 2 Major Segmentation (Classification, Application and etc.) Analysis

Chapter 3 Production Market Analysis

Chapter 4 Sales Market Analysis

Chapter 5 Consumption Market Analysis

Chapter 6 Production, Sales and Consumption Market Comparison Analysis

Chapter 7 Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 8 Marketing Channel Analysis

Chapter 9 Industry Chain Analysis

Chapter 10 Global and Regional Market Forecast

Chapter 11 Major Manufacturers Analysis

Chapter 12 New Project Investment Feasibility Analysis

Chapter 13 Conclusions

Continued…

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

Scott Harris

Sales Manager

Email ID: [email protected]

Phone No.: +1-561-448-7424

#MRSA Antibiotics market 2020 #MRSA Antibiotics market forecast #MRSA Antibiotics market insights #MRSA Antibiotics market price

0 notes

markettrendus · 3 years

Text

Global MRSA Antibiotics Market Growth by Manufacturers, Regions, Type and Application, Production, Revenue, Price and Gross Margin Analysis to 2022

Global MRSA Antibiotics market Report 2022 gives the in detail look into consider revealing insight into various business verticals. It incorporates key business factors which prompt market improvement and progression. Overall MRSA Antibiotics market report portions the business into different classifications in light of the assembling regions. The industry report gives the total learning which…

View On WordPress

#MRSA Antibiotics Market #MRSA Antibiotics Market Report

0 notes

myabhijitr · 3 years

Text

Informative Report On (COVID-19 Updates) Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is Generating Revenue of US$ 1,327.9 Million by 2027

The COVID-19 infection has expanded to over 100 nations since its breakout in December 2019, prompting the World Health Organization to designate it a public health crisis. According to a study published by the World Health Organization, coronavirus illness (COVID-19) has affected over 45 million people globally as of October 30, 2020. Due to the rising incidence of COVID-19, major companies in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market are focused on the research and development of new funds to enhance and counteract COVID-19’s effects. The COVID-19 pandemic has had a significant influence on the worldwide economy and, as a result, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market was also affected. Quarantines, travel restrictions, and social distancing measures are all expected to result in a significant drop in corporate and consumer expenditure until the third quarter of 2020.

Request for Analysis of COVID-19 Impact on Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market – https://www.coherentmarketinsights.com/insight/request-sample/1538

Overview

Antibiotic-resistant forms of the bacterium staphylococcus aureus produce methicillin-resistant staphylococcus aureus (MRSA). Based on the route of infection, methicillin-resistant Staphylococcus aureus (MRSA) can be classified into two types: hospital-associated MRSA infections (HA-MRSA) and community-associated MRSA infections (CA-MRSA). Invasive treatments, such as surgeries, intravenous tubing, and skin-to-skin contact, are the most common causes of this illness. MRSA medicines are used to treat or prevent infections caused by Methicillin-resistant Staphylococcus aureus. For the treatment of infections caused by MRSA, a variety of antibiotic medicines are available on the market.

In 2020, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market is anticipated to be worth US$ 984.6 million, growing at a CAGR of 4.4 percent during the forecast period (2020-2027).

Drivers

During the forecast period, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market is projected to expand due to an increase in new launches and clearances.

Infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) bacteria are becoming more common, causing public health concerns. Companies are concentrating on product research and releases for the diagnosis of Methicillin-resistant Staphylococcus aureus (MRSA), which is impelling the global Methicillin-resistant Staphylococcus aureus (MRSA) drugs market. NUZYRA (omadacycline) was introduced in the U.S. by Paratek Pharmaceuticals, Inc. in February 2019. The antibiotic is offered as an intravenous and oral once-daily dose. It was created to combat tetracycline resistance and work against a wide range of bacteria, particularly gram-positive, gram-negative, atypicals, and other drug-resistant species.

Request PDF Brochure Report – https://www.coherentmarketinsights.com/insight/request-pdf/1538

In addition, one of the crucial factors driving the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is the implementation of inorganic business expansion such as mergers, acquisitions, and partnerships by main players. In March 2019, Melinta Therapeutics signed an exclusive license, supply, and supply chain contract with Hikma Pharmaceuticals.

0 notes

blueweave01 · 3 years

Text

Global Antimicrobial Susceptibility Testing Market Proliferating & Projected to Reach Worth USD 4.70 Billion by 2027

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global antimicrobial susceptibility testing market was worth USD 3.19 billion in 2020 and is further projected to reach USD 4.70 billion by 2027. The emergence of multidrug-resistant microbial strains like MRSA, Klebsiella pneumonia, Acinetobacter baumanii, etc., is the primary cause of the growth of the global antimicrobial susceptibility market. Apart from that, the growing cases of infectious diseases across the globe, coupled with increasing government funding and initiatives, and automated rapid AST (Antimicrobial susceptibility testing) methods are some of the key factors aiding the rapid growth of the global antimicrobial susceptibility testing market.

Growing cases of infectious diseases acting as a catalyst for the global antimicrobial susceptibility testing market

According to Columbia University's Stephen Morse, emerging infections are infections that are rapidly expanding in frequency or geographic range, such as HIV/AIDS, severe acute respiratory syndrome (SARS), Ebola hemorrhagic fever, and Nipah virus encephalitis. The emergence of new infections and microbial strains into a host population and its establishment within the said population is mainly due to the vast and highly uncharacterized “zoonotic pool” of possible human pathogens as well as the increasing opportunities for infection caused by ecological upheaval and globalization.

Human activity, however, is making the transition very easy by creating efficient pathways for pathogen transmission around the globe. For example, the anti-vaxxers movement in the U.S. for flu vaccination led to a decrease in the vaccination rate. As a result, the vaccination rate in 2018 was 37.1% which was 6.2% lower than the vaccination rate in 2017. Due to such emergence of infectious diseases caused by human activities, AST has become imperative, thus aiding in the growth of the global antimicrobial susceptibility testing market.

Increasing prevalence of multidrug-resistant microbial strains making antimicrobial susceptibility testing an imperative process

Antimicrobial Agents (AMA) are the secondary metabolites produced by microorganisms that selectively suppress the growth or kill other microorganisms at a very low concentration with minimum injury to the host cell. Antibiotic-resistant bacteria are an essentially inevitable outcome of the extensive use of antimicrobial agents. The discovery, commercialization, and widespread administration of antimicrobial substances ushered in a new era in contemporary medicine, altering the therapeutic paradigm for treating infections. Unfortunately, the successful outcomes of critically sick patients have been jeopardized due to a considerable increase in antibiotic resistance among prevalent bacterial infections. As a result, antibiotic resistance is one of the three most serious public health problems of the 21st century, according to the World Health Organization.

The emergence of multidrug-resistant organisms in the hospital environment and community settings suggests that reservoirs of antibiotic-resistant bacteria are present even outside the hospital. The answer is "survival of the fittest," which explains the enormous genetic flexibility of bacterial pathogens that stimulate specialized reactions, culminating in mutational adaptations. Resistance to practically all antibiotics currently available in clinical practice results from the acquisition of genetic material or the modification of gene expression. Therefore, to prevent paradoxical worsening of the patient's condition due to over-medication or under-medication, antimicrobial susceptibility testing has become imperative to treat microbial infection, leading to the growth of the global antimicrobial susceptibility testing market.

Global antimicrobial susceptibility testing market by end-user

Based on the end-user, the global antimicrobial susceptibility testing market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research & academic institutes, clinical research organizations (CROS). The hospitals segment hold the largest share in the global antibiotic susceptibility testing market as they are prominent end-users of antimicrobial susceptibility testing products. The large share of hospitals is also due to the growing prevalence of hospital-acquired infections, such as Hospital-Acquired Pneumonia and Ventilator Acquired Pneumonia. Furthermore, due to the presence of high-tech and well-equipped facilities and equipment, as well as highly trained/skilled technicians in diagnostic laboratories, as well as various endeavors by important players to provide efficient AST products to diagnostic laboratories, the diagnostic center segment is likely to witness exemplary growth during the forecast period.

Global antimicrobial susceptibility testing market by region

Based on region, the global antimicrobial susceptibility testing market is segmented into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. Out of these regions, North America has the largest share of the global antimicrobial susceptibility testing market. TNorth America’s dominance can be attributed to the growing investment in R&D to develop novel automated AST systems, technological advancements in antimicrobial susceptibility products, and increasing cases of infections like Lyme Disease and West Nile. On the other hand, the Asia Pacific antimicrobial susceptibility testing market is also growing owing to the increasing public health awareness, increasing population, and over-consumption of antibiotics.

Impact of COVID-19

With the outbreak of the COVID-19, major industries and businesses, as well as people's daily lives, have been disrupted. To curb the spread of the COVID-19 virus, almost every country had to impose nationwide lockdown and. Since the pandemic, hospitals have prioritized COVID-19 treatment; consequently, the usage of automated antimicrobial susceptibility testing technologies such as the Accelerate Pheno system, MicroScan WalkAway system, and Sensitive ARIS system has been drastically reduced. Additionally, the stringent government rules and regulations during the pandemic on new product launches and instrument approval also severely impacted the global antimicrobial susceptibility testing market.

Competitive Landscape

The global antimicrobial susceptibility testing market is thriving owing to the growing prevalence of infectious diseases, emergence of antimicrobial-resistant strains, and government initiatives. As a result, the market is attracting many key players. Some of the key players in the global antimicrobial susceptibility testing market are PML Microbiologicals Inc., BioMérieux SA, QuantaMatrix Inc., MP Biomedicals, InvivoGen, Biotron Ltd, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics Limited, Bio-Rad Laboratories, Inc., Merck KGaA, Accelerate Diagnostics, Inc., Liofilchem S.r.l., ZHUHAI DL BIOTECH Co., Ltd., ELITechGroup, Halifax S.r.l., Hi-Media Laboratories, Genefluidics, Inc., Creative Diagnostics, and other prominent players.

Don’t miss the business opportunity of the global antimicrobial susceptibility testing market. Consult our analysts to gain crucial insights and facilitate your business growth.

The report's in-depth analysis provides information about growth potential, upcoming trends, and statistics of the global antimicrobial susceptibility testing market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the global antimicrobial susceptibility testing market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

Blue Weave Consulting provides all-inclusive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost your business solution's performance. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are a promising digital MI solutions company providing agile assistance to make your business endeavors successful.

0 notes

rishabhcmi · 4 years

Text

SINUS DILATION DEVICES MARKET ANALYSIS

Sinus dilation devices play a major role in modern healthcare, allowing the sinus openings to expand during nasal sinusitis and are preferred over antibiotics, decongestants, or steroids, as it provides long-lasting and immediate results.

The global sinus dilation devices market was valued at US$ 2.7 billion in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2018 – 2026).

Figure 1. Global Sinus Dilation devices Market Value (US$ Mn), by Region, 2017

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of chronic sinusitis is expected to propel growth of the sinus dilation devices market

Sinus dilation device is used in nasal sinusitis and nose drainage issues. High prevalence of chronic sinusitis is expected to propel demand for of sinus dilation devices, which in turn is expected to drive the market growth. According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis. Chronic sinusitis affects 146 per 1000 people in the U.S., while in Canada the estimated prevalence of diagnosed chronic sinusitis is around 2% to 2.5% of the population. Sinusitis results in over 18-22 million physician visits per year in the U.S. The socioeconomic burden is valued at US$ 3.4-5 billion annually, for the treatment of this chronic sinusitis.

Furthermore, according to the study published in the U.S. National Library of Medicine, up to 64% of the patients suffering from acquired immune deficiency syndrome (AIDS) have possibility to develop chronic sinusitis in their course of life.

However, complications such as excessive and prolonged bleeding, post-surgical infections, which can be life threatening such as Methicillin-Resistant Staphylococcus Aureus (MRSA), and rare complications such as cerebrospinal fluid rhinorrhea are expected to limit adoption of sinus dilation devices, thereby hindering the market growth.

A study conducted by American Journal of Rhinology & Allergy in 2014, suggested that the complication rate for balloon sinuoplasty (BSP) was 5.26% and it was 7.35% for conventional functional endoscopic sinus surgery (FESS). Major complications associated with the endoscopic surgeries are due to balloon sinuplasty

Figure 2. Global Sinus Dilation Devices Market Share (%), by Design, 2018 and 2026

Source: Coherent Market Insights Analysis (2018)

Increasing adoption of sinus dilation devices in North America is expected to boost growth of the market

North America holds dominant position in the global sinus dilation devices market, owing to high availability of sinus dilation devices in medical settings. Medications such as antibiotics and topical steroids help to open up blocked sinus passages and relieve symptoms. However, these medicines serve as short-term relive and do not fix the condition permanently, therefore, many people in the U.S. are adopting surgical methods for the treatment of this condition. According to the research published in the National Center for Biotechnology Information (NCBI), over 600,000 ambulatory sinonasal cases are performed each year in the U.S.

One of the minimally invasive and most favorable technique is Balloon Sinus Dilation (BSD). The balloon sinus dilation opens inflamed sinuses restoring normal sinus drainage and function often without tissue or bone removal. According to Entellus Inc.’s annual report, around 552,000 patients underwent FESS procedures in the U.S. in 2015. Out of which, over 55% were well suited for balloon sinus dilation, and the supplementary 30% were apt for hybrid balloon sinus dilation (BSD with FESS).

Key Players

Major players operating in the global sinus dilation devices market include, Entellus Medical, Inc., Smith & Nephew Plc., Acclarent, Inc., B. Braun Melsungen AG, Medtronic Plc, Olympus Corporation, SinuSys Corporation, InnAccel Technologies, and Intersect ENT, Inc.

Request the sample copy of here:

https://www.coherentmarketinsights.com/insight/request-sample/2451

Download the PDF Brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2451

Buy now the market research report here:

https://www.coherentmarketinsights.com/insight/buy-now/2451

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: [email protected]

Source:

https://www.coherentmarketinsights.com/market-insight/sinus-dilation-devices-market-2451

0 notes

amshrihari · 4 years

Text

SMALL MOLECULE ANTI-INFECTIVE DRUG MARKET ANALYSIS

Small Molecule Anti-infective Drug Market, by Product Type (Antibiotics (B Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamides, and Others), Antifungal ( Azoles, Echinocandins, Polyenes, and Others), Antivirals (Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside Reverse Transcriptase Inhibitors, and Others), and Others (Anthelminthic and Antiprotozoal), by Indication (Pneumonia, MRSA Infections, MSSA Infections, Sinusitis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis, Hepatitis, HIV Infection, Respiratory Tract Infection, Urinary Tract Infection, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

Source https://www.coherentmarketinsights.com/ongoing-insight/small-molecule-anti-infective-drug-market-2655

Small molecule anti-infective drugs are used for the treatment of various infectious diseases such as Methicillin-resistant Staphylococcus aureus (MRSA) infections, Methicillin-Susceptible Staphylococcus aureus (MSSA) infections, sinusitis, cellulitis, pneumonia, tuberculosis, aspergilosis, and hepatitis. Anti-infective drugs have the capability to eliminate and suppress infections that are caused by various bacteria and viruses.

Small Molecule Anti-infective Drug Market Drivers

Increasing approval of new drugs is expected to drive growth of the global small molecule anti-infective drug market. For instance, in April 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Dovato (dolutegravir and lamivudine), which is used for the treatment of HIV-1 infection in adults. It is manufactured by ViiV Healthcare.

Furthermore, in August 2018, Tetraphase Pharmaceuticals received the U.S. Food and Drug Administration approval for its new drug, Xerava containing Eravacycline, which is used for the treatment of complicated intra-abdominal infections (CIAI).

Request Sample

https://www.coherentmarketinsights.com/insight/request-sample/2655

Download PDF

https://www.coherentmarketinsights.com/insight/request-pdf/2655

Small Molecule Anti-infective Drug Market Restraints

Increasing severe side effect of drugs is the major restraining factor of anti-infective drug market, it is expected to the hamper the small molecule anti-infective drug market growth. For instance, NBC news report in December 2018, U.S Food and drug administration sends warning letters to Fluroquinonolone antibiotics because U.S FDA found that Fluroquinolones antibiotic can increase the occurrence of serious events of rupture in the main artery of the body. These ruptures called as the aortic dissections.

Small Molecule Anti-infective Drug Market Regional Analysis

On the basis of region, the global small molecule anti-infective drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the small molecule anti-infective drugs market, owing to new product launches of small molecule anti-infective drugs. For instance, in November 2018, Xellia Pharmaceuticals launched its new product, Vancomycine Hydrochloride for injection, in the U.S market.

Furthermore, Asia Pacific is also projected to witness significant growth in the global small molecule anti-infective drugs market, owing to increasing collaboration activities among key players. For instance, in April 2018, Entasis Therapeutics Holdings Inc. collaborated with the Zai Lab Limited. This collaboration facilitated phase III clinical trial for a fixed-dose combination of ETX2514 and sulbactam. This combination is intended for the treatment of multidrug-resistant infections caused by Acinetobacter baumannii bacteria. The study started in April 2019 and is expected to complete in July 2020.

Key players operating in the global small molecule anti-infective market include, Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc.

Small Molecule Anti-infective Drug Market Taxonomy

By Product Type

Antibiotics

Antifungal Drugs

Antiviral Drugs

Others

B Lactam

Quinolones

Macrolides

Tetracyclines

Aminoglycosides

Sulphonamide

Others

Azoles

Echinocandins

Polyenes

Others

Nucleoside Reverse Transcriptase Inhibitors,

Non-nucleoside Reverse Transcriptase Inhibitor

Others

Anthelminthic

Antiprotozoal

By Indication

Pneumonia

MRSA Infections

MSSA Infections

Sinusitis

Tuberculosis

Dermatophytosis

Aspergillosis

Candidiasis

Hepatitis

HIV Infection

Respiratory Tract Infection

Urinary Tract Infection

Others

By Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

About Us:

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: [email protected]

0 notes

stylford · 4 years

Text

Dr. Bailey's Enthusiasm for Bust Cancer Cells Campaigning For

Breast cancer cells hit me tough with shock as well as fear in 2013. It's still front and facility in my life with gratitude as well as acceptance. I made it through, I discovered, my life altered, and also I fulfilled some incredible people that I otherwise would certainly not have.

Going from shock and horror to appreciation and acceptance included a ton of lessons, although I really did not succumb to them a few of them conveniently. I know that what I eventually discovered can assist others who are currently encountering the bust cancer treatment gauntlet. These lessons are also of worth to any individual dealing with other kinds of serious health problem.

October is Breast Cancer Understanding Month. I've been sharing what I have actually learned from The Cancer cells Year this October to pay it ahead for those strolling the path currently. Here is a wrap-up of my advocacy job from this October, 2019. If you understand a person that might take advantage of these resources today, please share:

1. I was welcomed by The Press Democrat, our Pulitzer Reward winning newspaper, to create a short article regarding the experience as well as lessons discovered as a physician-turned-patient with bust cancer cells. Find the story right here, A Doctor Shares Instructions She Learned as a Breast Cancer Cells Client.

2. I shot a Facebook Live video clip reviewing my experience and also lessons discovered in the hopes helpful others who are currently being treated for bust cancer or other major health problems. During The Cancer cells Year I integrated the bottom lines that helped me defeat a negative prognosis as well as make it through. Find my video below. Please keep in mind to "Follow" the web page to see even more of my Facebook Live Videos.

3. Eva SooHoo, the owner of Eileen & Eva, featured my work as well as my Chemotherapy Skin Treatment Set on her blog and Facebook site. Eva and also I share a passion to sustain the breast cancer neighborhood. She produced a soothing garments line for bust cancer treatment, with special functions such as pockets for the post medical drains! We girls that have actually walked this course understand the offer, as well as Eva is making it much easier for those currently being treated.

Eva and also I are both BRCA mutation carriers. We have had a lot of surgery to make it through cancer cells and/or previve cancer. Eva produced Eva&& Eileen's Heal Snappy Collection to use,

sophisticated as well as practical clothing for cancer cells people, where drains pipes, PICC lines as well as ports are fit without compromising the loveliness and poise of layout ... Each garment is made with hand-crafted describing, flattering lines as well as quality building and construction. Our proprietary Tencel ™ blend is luxuriously soft for delicate skin, and also is breathable, moisture wicking as well as anti-microbial to moderate the impact of warm flashes. Our collection of clothing for cancer cells clients is adoringly developed as well as made in California.

Eva supports breast cancer cells individuals, as well as breast and ovarian cancer previvors with her attractive garments. Likewise, I created my Chemotherapy Skin Care Set to do the exact same. My Chemo Package is based on my very own chemo experience as well as my professional experience as a dermatologist that has sustained chemo clients for 30+ years.

When I was ill, I located that no sufficient product existed for chemotherapy skin care. Products marketed to chemo clients teemed with get in touch with irritants and/or were not really therapeutic. I developed my chemo kit to make sure that chemo clients would certainly have whatever they require to maintain their at risk skin healthy throughout this physiologically difficult time.

The reality is that our skin is our greatest body organ. It gets on the outside of our bodies and is subjected to dangerous germs daily - such as those that cause significant infections like Staph, MRSA, Strep etc. Chemo clients have subdued immune systems, and also are at risk to infections from these common germs. Obtaining a skin infection obtains them place on prescription antibiotics, which results in yeast infections. This comes to be a severe cycle that chemo individuals need to stay clear of. My kit keeps the skin healthy and balanced, therefore protecting against or detaining this cycle.

The various other very amazing aspect of my Chemo kit is that I give all of the revenue to FORCE, the campaigning for organization for the hereditary breast and also ovarian cancer cells area. With every kit marketed, Dr. Bailey Skin Care sends out a check to COMPEL! REQUIRE was there for me when I was unwell, as well as I want them to remain to be there for all those on the cancer cells misadventure being available in after me.

Breast cancer cells transformed my life-- and also it's not all sad or bad. The fear I really felt going into the procedure has evolved to thankfulness. I have many people to give thanks to and so much insight I have actually gotten. Every October brings it all front and also facility once more for me. Please share these resources with those that may discover them of value.

In Appreciation,

Cynthia Bailey, MD,

Skin doctor, BRCA1 mutation provider, Breast Cancer cells Survivor, Ovarian Cancer cells Previvor (ideally), as well as Bust Cancer Supporter

0 notes

adwaitcoherent · 4 years

Text

By 2026, Global Sinus Dilation Devices Market To Surpass US$ 5.7 Billion - Coherent Market Insights

Global Sinus Dilation Devices Market To exhibit a CAGR of 8.4% over the forecast period (2018 – 2026)

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2451

Description:

The global sinus dilation devices market was valued at US$ 2.7 billion in 2017, and is expected to exhibit a CAGR of 8.4% over the forecast period (2018 – 2026).

Figure 1. Global Sinus Dilation devices Market Value (US$ Mn), by Region, 2017

sinus dilation devices market fig1

Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of chronic sinusitis is expected to propel growth of the sinus dilation devices market

Figure 2. Global Sinus Dilation Devices Market Share (%), by Design, 2018 and 2026

sinus dilation devices market fig2

Source: Coherent Market Insights Analysis (2018)

Increasing adoption of sinus dilation devices in North America is expected to boost growth of the market

Key Players

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2451

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Market Analysis #Market Research #Coherent Market Insights

0 notes

healthcare00897 · 5 years

Text

Anti-infective Drugs Market Shows at a Rapid Pace Until 2026

Infectious diseases are health disorders that are caused by invasion and multiplication of infection-causing foreign organisms in a host’s body. Growth and multiplication of harmful pathogens such as bacteria, viruses, fungi, and parasites causes major infections in the host body. Infection can be transmitted through skin contact, bodily fluids, airborne particles, or touching an infected object. Anti-infective drugs are used for the treatment of infectious diseases or conditions. Anti-infective drugs act by inhibiting the growth or by eliminating the infectious agents.

Get Exclusive Sample Report at: https://www.coherentmarketinsights.com/insight/request-sample/2489

Anti-infective Drugs Market: Drivers

Key players in the market are focused on new product launch, which is expected to boost the anti-infective drugs market growth. For instance, in January 2018, Melinta Therapeutics, Inc. launched its intravenous and oral formulations of Baxdela (delafloxacin) in the U.S. Baxdela is intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria including gram positive bacteria and gram negative bacteria.

Moreover, increasing prevalence of sepsis is expected to boost growth of the anti-infective drug market. Sepsis is a life-threatening condition caused by the body’s response to an infection. For instance, according to the World Health Organization’s (WHO) report, 2018, over 30 million people worldwide are affected with sepsis that leads to 6 million deaths, annually. Moreover, over three million newborns and 1.2 million children suffer from sepsis worldwide, annually.

Furthermore, increasing number of pipeline studies to develop anti-infective drugs for the treatment of rare infectious diseases is contributing to growth of the anti-infective drugs market. For instance, in January 2019, National Institute of Allergy and Infectious Diseases (NIAID) initiated phase 2/phase 3 clinical trial to study the safety and effectiveness of four drugs including ZMapp, Remdesivir, MAb114, REGN-EB3, in people with Ebola virus infection. The study is expected to be complete by November 2024.

However, hypersensitivity reactions associated with administration of anti-infective drugs is expected to hamper growth of the anti-infective drugs market. For instance, in 2013, Clinical Infectious Diseases reported that in the study of self-reported antibiotic allergy prevalence, there was 9.0% of patients among 411 543 outpatients had a penicillin allergy documented in their medical record in San Diego County, California.

Anti-infective Drugs Market: Regional Analysis

On the basis of region, the global anti-infective drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to witness significant growth in the anti-infective drugs market over the forecast period. This is owing increasing expansion activities by key players in this region. For instance, in September 2018, Xellia Pharmaceuticals, a specialty pharmaceutical company that offers anti-infective drugs against serious and often life-threatening infections, started its new office in Buffalo Grove, near Chicago, Illinois to expand its sales and manufacturing capabilities within the U.S.

Furthermore, Asia Pacific is expected to witness significant growth in the anti-infective drugs market over the forecast period owing to new product launches in this region. For instance, in September 2018, Astellas Pharma Inc. launched Dafclir Tablets 200 mg (fidaxomicin) for the treatment of infectious enteritis (including pseudomembranous colitis) in Japan. Astelles has also made an agreement with Merck in 2018 for development and marketing of Dafclir in Japan.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2489

Global Key Players:

Key players operating in the anti-infective drugs market include, Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc., Bayer HealthCare AG, Alkem Labs, Pacific India Pharma Limited, Pfizer, and others.

Anti-infective Drugs Market Taxonomy

By Drug Class Type

Anti-bacterial Drugs

B – Lactams

Quinolones

Macrolides

Tetracycline

Aminoglycoside

Others

Anti-fungal Drugs

Azoles

Echinocandins

Polyenes

Others

Anti-viral Drugs

By Indication Type

Pneumonia

Methicillin-resistant Staphylococcus Aureus (MRSA)

Sepsis

Tuberculosis

Dermatophytosis

Aspergillosis

Candidiasis

Hepatitis Virus Infection

HIV Infection

Respiratory Virus Infection

Others

By Route of Administration

Oral

Topical

Parenteral

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Region

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

0 notes

pharmaphorumuk · 7 years

Text

Ground-breaking research in continuous fight against AMR

The BBC recently reported on US’s scientists discovery of a new family of antibiotics in soil samples. The natural compounds could be used to combat hard-to-treat infections, the team at Rockefeller University hopes. Tests show the compounds, called malacidins, annihilate several bacterial diseases that have become resistant to most existing antibiotics, including the superbug MRSA. Experts say the work, published in Nature Microbiology, offers fresh hope in the antibiotics arms race.*

It is imperative for medical experts and drug discovery specialists to stay on top of the latest clinical advancements, developments and industry initiatives related to antimicrobial resistance.

SMi’s 20th annual conference on Superbugs and Superdrugs (19 – 20 March 2018, London) will gather experts representing government bodies and top organisations to share their insights with you.

Get your ticket on the website http://www.superbugssuperdrugs.com/pharmaphorum

NEW INTERVIEW RELEASED

Mark Albrecht, Health Scientist, HHS/ASPR/BARDA has participated in a comprehensive interview and here is the snapshot of what he has to say.

SMi: What do you believe are the biggest challenges associated currently with tackling the threat of antimicrobial resistance?

Mark Albrecht: There are a variety of challenges… however, there has been greater discussion regarding the lower commercial returns antibiotics generate compared to other therapeutic areas such as cancer or heart disease. Given that antibiotic development is financially challenging with an uncertain return on investment (ROI) it is clear that both push mechanisms (CARB-X, GARD-P, NIAID, Wellcome Trust, BARDA, etc.) and pull incentives are necessary. In particular, pull incentives will ensure companies have a predictable ROI for developing these drugs that society requires, but undervalues.

Full interview is available on the Download Centre http://www.superbugssuperdrugs.com/pharmaphorum

An independent report looking at the pharma industry’s efforts to tackle AMR says the sector is doing “better than expected” but is still not on track to avert a potential healthcare crisis.**

Mark Albrecht’s presentation at the event will be looking at the ways to incentivize antibacterial research and development.

NEW SPEAKERS

John Rex, Chief Medical Officer at F2G Ltd and Emmanuelle Coutanceau, Partner at Novo Holdings join the speaker line-up at the Superbugs and Superdrugs Conference.

In his presentation John Rex will look into the issues of funding, including updates on CARB-X initiative

STAY CONNECTED

LinkedIn – search ‘SMi Pharma’

Twitter – @SMIpharm #smibugs

——————————————————————————————-

Superbugs & Superdrugs Conference | 19 – 20 March 2018 | London, UK http://www.superbugssuperdrugs.com/pharmaphorum

——————————————————————————————-

* BBC News – New antibiotic family discovered in dirt, 13 February 2018

**Pharmaceutical Market Europe – February 2018, page 9

The post Ground-breaking research in continuous fight against AMR appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/ground-breaking-research-in-continuous-fight-against-amr/

0 notes

expertofmarketinsights-blog · 5 years

Text

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market To Register Unwavering Growth During in Global by 2026

Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital Associated MRSA Infection (HA-MRSA) or community-associated MRSA infections (CA-MRSA). Staphylococcus aureus leads to skin infections such as boils, pimples, impetigo, abscesses or certain life threatening conditions such as septicemia (blood poisoning), pneumonia (lung infection), osteomyelitis (bone infection), endocarditis (heart valve infection), urinary tract infection, and septic bursitis (formation of small fluid-filled sacs under the skin). Growth of the methicillin-resistant staphylococcus aureus (MRSA) drug market is driven by increasing product pipeline and increasing adoption of organic and inorganic strategies by key market players. Click To Read More On Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver

Increasing number of pipeline products for the treatment of methicillin resistance staphylococcus aureus infection is expected to fuel growth of the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market during the forecast period. For instance, in 2014, Cubist Pharmaceuticals Inc., received US FDA approval for its new antibiotic, Sivextro, available in both the forms – injection as well as oral, to treat skin infection caused by gram positive bacteria including MRSA. Moreover, new route of administration are experimented by market players to treat MRSA infection. For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat with post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). These increasing number of product approvals is expected to aid in growth of the MRSA drugs market over the forecast period.

Moreover, funding programs by healthcare organization will also propel drug discovery and development program, in turn leading to growth of the MRSA drug market. For instance, in 2017, Cystic Fibrosis Foundation Therapeutics (CFFT)—a non-profit drug discovery and development arm of Cystic Fibrosis Foundation—awarded US$ 5 million to Savara Inc., a clinical-stage specialty pharmaceutical company, for the development of AeroVanc, vancomycin hydrochloride inhalation powder, intended to treat MRSA lung infection in individual with cystic fibrosis.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Competitor

Key market player in methicillin-resistant staphylococcus aureus (MRSA) drugs market are Basilea Pharmaceutica Ltd., Cubist Pharmaceuticals Inc., Melinta Therapeutics, Inc., Theravance Biopharma, Allergan, Merck & Co., Xellia Pharmaceuticals ApS (owned by Novo Holdings A/S), King Pharmaceuticals Inc. (a wholly owned subsidiary of Pfizer), and PF Prism C.V. Players in the market are focusing inorganic growth strategies in order to enhance its market share and remain competitive in the market.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1538

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market - Regional Analysis

Geographically, global methicillin-resistant staphylococcus aureus (MRSA) drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in methicillin-resistant staphylococcus aureus (MRSA) drugs market, owing to increasing research and development studies by key market players to come up with new drug. For instance, in 2016, Allergan plc received US FDA approval for Dalance in injectable form for acute bacterial skin and skin structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA). Asia Pacific is expected to witness fastest growth over the forecast period. This is due to larger patient pool and increasing market player’s strategies to expand their geographical reach in this region.

About Coherent Market Insights:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market #Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size #Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Share #Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Outlook #Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs

0 notes

amshrihari · 4 years

Text

GRAM POSITIVE BACTERIAL INFECTIONS MARKET ANALYSIS

Gram Positive Bacterial Infections Market, by Drug Class (Antibiotic (B Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamides, Phenicols, and Others), Antifungal, and Others), by Indication (MRSA Infections, MSSA Infections, Sinusitis, Cellulitis, Pneumonia, Otitis, Pharyngitis, and Others), by Route of Administration (Enteral, Parenteral, and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

Source

https://www.coherentmarketinsights.com/ongoing-insight/gram-positive-bacterial-infections-market-2654

Bacteria are classified into two main types: gram positive bacteria and gram negative bacteria. After staining, gram positive bacteria shows violet purple color under microscope. Gram positive bacteria cause various infections such as Methicillin- resistant Staphylococcus aureus (MRSA) infections, Methicillin-Susceptible Staphylococcus aureus (MSSA) infections, sinusitis, cellulitis, and pneumonia.

Gram Positive Bacterial Infections Market Drivers

Increasing drug approvals are expected to propel growth of the gram positive bacterial infections market. For instance, in October 2018, Paratek Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration for NUZYRA (for injection), which contains an Omadacycline. This drug is used for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

Increasing drug launches are expected to drive the gram positive bacterial infections market growth. For instance, in March 2017, Pfizer launched its new drug, Zavicefta, which contains combination of Avibactam and Ceftazidime. This drug is used for the treatment of intra- abdominal infections.

Gram Positive Bacterial Infections Market Restraints

Antibiotic resistance is the major problem in the treatment of gram positive bacterial infections, which is expected to hamper the market growth. For instance, in October 2018, according to the Centers for Disease Control (CDC) and Prevention, overdose of antibiotics can lead to resistance and around 2 million people are affected with antibiotic resistance in the U.S annually.

Gram Positive Bacterial Infections Market Regional Analysis

On the basis of region, the global gram positive bacterial infections market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the gram positive bacterial infections market, owing to increasing launch of antibacterial drugs acting against gram positive bacteria. For instance, in January 2018, Melinta Therapeutics, Inc. launched its new drug, Baxdela antibiotic containing Delafloxacin, for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Request Sample

https://www.coherentmarketinsights.com/insight/request-sample/2654

Download PDF

https://www.coherentmarketinsights.com/insight/request-pdf/2654

Europe is also expected to witness significant growth in the gram positive bacterial infections market, owing to increasing collaboration and acquisition activities adopted by market players. For instance, in March 2019, Evotec AG (headquartered in Germany) collaborated with the Global Antibiotic Research and Development Partnership (GARDP). This collaboration focuses on accelerating the development of novel antibiotic treatments.

Key players operating in the global gram positive bacterial infections market include, Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc.

Gram Positive Bacterial Infections Market Taxonomy

By Drug Class

Antibiotic

Quinolones

Macrolides

Tetracyclines

Aminoglycosides

Sulphonamides

Phenicols

Others

Antifungal

Others

By Indication

MRSA Infections

MSSA Infections

Sinusitis

Cellulitis

Otitis

Pharyngitis

Others

By Route of Administration:

Enteral

Parenteral

Others

By Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

Europe

Asia Pacific

Latin America

Middle East

Africa

About Us:

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email:

[email protected]

0 notes

theshadowytastemakerstuden-blog1 · 5 years

Text

Global MRSA Antibiotics Market Survey by Demand, Opportunities, Trends, Solutions and SWOT Analysis 2019

Researchmoz added Most up-to-date research on “Global MRSA Antibiotics Market Research Report 2019-2025 ” to its huge collection of research reports.

Methicillin-resistant staphylococcus aureus (MRSA) infections cause range of illnesses, notably including soft-tissue abscesses, bacteremia, pneumonia, and sepsis syndromes. The growing prevalence of MRSA in various parts of the world, especially in the U.S., has been a serious health concern, paving way for large unmet need for drugmakers. Antibiotics have particularly emerged as promising in community-associated MRSA in numerous settings, especially in skin and soft-tissue infections. In this regard, empiric therapy for MRSA has gained popularity in patients in initial few days of treatment. The growing incidence of MRSA in children and old adults is catalyzing the prospective demand for MRSA antibiotics. Developments in this regard has been increasingly bolstered by evidence-based guidelines. Advent of antibiotic agents will create new avenues from 2019 to 2025, during which the market will clock a promising CAGR.

For more info, Get Free Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=2339541

In 2019, the market size of MRSA Antibiotics is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for MRSA Antibiotics.

This report studies the global market size of MRSA Antibiotics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the MRSA Antibiotics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered: Pfizer Sanofi Novartis …

Market Segment by Product Type Vancomycin Teicoplanin Linezolid Cubicin Others

Market Segment by Application Adults Children

Key Regions split in this report: breakdown data for each region. United States China European Union Rest of World (Japan, Korea, India and Southeast Asia)

Place an Enquiry to Our Industry Expert @ https://www.researchmoz.us/enquiry.php?type=E&repid=2339541

The study objectives are: To analyze and research the MRSA Antibiotics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast. To present the key MRSA Antibiotics manufacturers, presenting the sales, revenue, market share, and recent development for key players. To split the breakdown data by regions, type, companies and applications To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends, drivers, influence factors in global and regions To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of MRSA Antibiotics are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact: ResearchMoz Mr. Nachiket Ghumare, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Website: https://www.researchmoz.us Email: [email protected] Blog: https://blogreportstudy.blogspot.com/

0 notes

rohit09exactitudeconsultancy · 5 years

Text

MRSA Drugs Market Product Designs, Manufacturer Details, Forecasts to 2022

Market Overview

Methicillin-resistant Staphylococcus aureus (MRSA) is an antibiotic resistant strains of the pathogen. MRSA infections are classified as hospital-acquired (HA-MRSA) or community-acquired (CA-MRSA). MRSA causes infections such as skin infections, bone and joint infections, bacteremia, animal infections and others.

According to bulletin of the atomic scientists, about 10 million people in the US (3.6 percent of the population) are immune-compromised. The World Health Organization estimated that about 36.7 million people had HIV/AIDS worldwide in 2016. Thus, the rising immune-compromised population is expected to propel the market growth over the review period.

Additionally, growing geriatric population projected to support the growth of the market since older people are more susceptible to MRSA infections. World Health Organization estimated that during 2015-2050, the proportion of the world's population will be nearly double from 12% to 22% and by 2020, the number of people aged over 60 years likely to outnumber children younger than 5 years.

Latest Research Insights at https://www.marketresearchfuture.com/press-release/mrsa-drugs-market

Segmental Analysis:

The global MRSA drugs market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.

Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.

Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).

Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Competitive Analysis:

Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V, Novartis, and others.

Regional Analysis:

The Americas accounts for a significant market share owing to high expenditure on the health care. The fastest uptake of new drugs in the US drives the MRSA drugs market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP that also increases the sale in MRSA drugs market.

Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. Italy is expected to be the fastest growing region over the assessment period.

And Many More

Brows Complete Detailed Research Report at https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Market Research Future

+1 646 845 9312

Email: [email protected]

#MRSA Drugs Market

0 notes